Health-API Ecosystem Board Adviser

The mandate

The network is opening its health-record and care-coordination interfaces to laboratories, pharmacies, insurers, digital-care providers and smaller hospitals. Founding institutions expect influence over standards, new participants fear costly conformance, and patient advocates question whether technically valid consent reflects meaningful choice. The board’s recurring question is how participation rules and partner economics can broaden useful exchange without creating a closed club, unsafe data reuse or a lowest-common-denominator clinical record.

The adviser will review monthly ecosystem evidence, run pre-board challenge with technical and clinical owners, attend quarterly Mumbai sessions and observe two provider networks. The cadence will examine partner categories, consent comprehension, identity and delegation, data quality, conformance burden, support models, change governance, certification failure and incentives to contribute complete information. Advice will identify distributional effects on smaller providers and patients, not only aggregate connection counts.

The appointment lasts twelve months and ends after two participation-rule releases and a network-economics review. Renewal is possible only through a recorded board decision that identifies a new question beyond the initial partner-governance mandate and confirms that management can operate the conformance process independently. The intended outcome is stronger institutional judgement, not permanent external oversight of ordinary API changes.

The role conveys no line authority and assigns no executive responsibility for API releases, clinical policy, consent operations, participant admission, commercial contracts, privacy determinations or security risk. Management supplies recommendations and runs the network; directors approve reserved rules. The adviser may request patient or provider evidence and record a contrary view, but cannot serve as a shadow conformance body.

Conflicts and disclosures cover healthcare providers, laboratories, pharmacies, insurers, digital-health companies, standards bodies, technology vendors, investors and public programmes. The adviser must recuse from deliberation affecting a connected organisation, cannot promote a vendor or participant, and will not accept contingent payment tied to membership, transaction volume or public policy outcomes. Patient-level data stays inside approved client environments.

Why the board wants this voice

Technical teams can demonstrate standards conformance while provider leaders focus on workflow cost and advocates focus on comprehension and agency. Those views reach the board as separate presentations, making trade-offs hard to see. A health-platform ecosystem leader can connect technical participation, clinical usefulness, consent legitimacy and network economics, while challenging growth measures that reward connection even when exchanged information is incomplete or unused.

What you will own

• Challenge partner segmentation across care providers, diagnostics, pharmacy, payer, digital-care and patient-authorised service models.
• Examine consent journeys for comprehension, delegation, withdrawal, purpose change and consequences when care depends on exchanged information.
• Test conformance obligations against clinical usefulness, data completeness, implementation cost, support capacity and smaller-provider access.
• Review certification, monitoring, suspension and remedy rules for proportionality, transparency and accountable patient-safety escalation.
• Assess partner incentives to contribute timely information, resolve quality defects and invest in workflows beyond minimum technical connection.
• Give directors explicit options where ecosystem growth, commercial sustainability, privacy and equitable participation pull apart.
• Leave a board scorecard spanning meaningful use, consent integrity, conformance outcomes, network concentration and patient benefit.

Candidate qualifications

• Has governed a multi-party health-data or interoperability ecosystem with providers, technology partners and patient-facing consent.
• Understands clinical data quality, identity, delegation, conformance, purpose limitation and workflow adoption beyond interface specifications.
• Has designed participation rules that smaller providers could meet without weakening safety, privacy or data-completeness expectations.
• Can evaluate network economics without treating connection volume, API traffic or institutional prestige as sufficient public value.
• Has worked credibly with patient representatives, clinicians, privacy counsel, engineers, payers and competing provider executives.
• Preserves formal clinical, security and privacy accountability while giving boards clear independent challenge on ecosystem consequences.

Non-negotiables

• Can attend quarterly Mumbai sessions and both designated provider-network observations across the twelve-month appointment.
• Will disclose every relevant provider, payer, vendor, standards, investment and public-programme relationship before evidence access.
• Brings health interoperability governance at network scale; single-provider integration delivery alone does not meet the requirement.
• Will refuse participant-sponsored compensation and protect patient-level information inside authorised client research environments.

1. 49 words maximum. Which technically conformant health-data exchange still failed to support a useful clinical decision?
2. 49 words maximum. How would you test whether a consent journey represents comprehension rather than interface completion?
3. 49 words maximum. What participation rule could unintentionally exclude a capable smaller healthcare provider?